BTI
IBRX icon

Blue Trust Inc’s ImmunityBio IBRX Stock Holding History

Blue Trust Inc’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.85K Sell
668
-104
-13% -$787 ﹤0.01% 2003
2026
Q1 		$5.92K Buy
+772
New +$5.29K ﹤0.01% 1957

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Blue Trust Inc's IBRX Position: Q2 2026 in Review

Blue Trust Inc reduced its ImmunityBio (IBRX) stake by 13% in Q2 2026, selling an estimated $787 and leaving 668 shares worth $5.85K. The position accounts for ﹤0.01% of the portfolio, ranked #2003.

Blue Trust Inc first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.92K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Blue Trust Inc held 668 shares of ImmunityBio worth $5.85K as of Q2 2026.
  • Blue Trust Inc sold 104 ImmunityBio shares in Q2 2026, an estimated $787.
  • ImmunityBio made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2003 holding.
  • Blue Trust Inc first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • Blue Trust Inc's ImmunityBio position peaked at $5.92K in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.